Hoe verhoudt 2289's PE Ratio zich tot zijn concurrenten?

2289 is duur op basis van de Price-To-Earnings -ratio ( 18.4 x) vergeleken met het gemiddelde van de peer ( 15.8 x).

Hoe verhoudt 2289's PE Ratio zich tot andere bedrijven in de HK Healthcare industrie?

2289 is duur op basis van de Price-To-Earnings -ratio ( 18.4 x) vergeleken met het Hong Kong Healthcare -industriegemiddelde ( 13.1 x).

Wat is 2289's PE Ratio vergeleken met zijn Fair PE Ratio? Dit is de verwachte PE Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

Onvoldoende gegevens om de Price-To-Earnings Fair Ratio van { 2289 te berekenen voor waarderinganalyse.

Wat is de reële prijs van 2289 als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

2289 ( HK$9.5 ) handelt boven onze schatting van [[eerlijke waarde]] ( HK$3.02 )

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

Er zijn onvoldoende gegevens om een prijsvoorspelling te tonen.

Charmacy Pharmaceutical (SEHK:2289) - Aandelenkoers, Nieuws & Analyse

2289 Overzicht aandelen

Charmacy Pharmaceutical Co., Ltd. houdt zich bezig met de distributie van farmaceutische producten in de Volksrepubliek China. Meer informatie

2289 fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	0/6
Prestaties in het verleden	2/6
Financiële gezondheid	2/6
Dividenden	2/6

Risicoanalyse

Rentebetalingen worden niet goed gedekt door de winsten

Winstmarges (1.2%) zijn lager dan vorig jaar (2.1%)

Dividend van 3.4% wordt niet goed gedekt door vrije kasstromen

Charmacy Pharmaceutical Co., Ltd. Concurrenten

Shanghai Pioneer Holding

SEHK:1345

HK$2.4b

IVD Medical Holding

SEHK:1931

HK$2.7b

Sinco Pharmaceuticals Holdings

SEHK:6833

HK$365.9m

Guanze Medical Information Industry (Holding)

SEHK:2427

HK$408.5m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Charmacy Pharmaceutical
Historische aandelenkoersen
Huidige aandelenkoers	HK$9.50
52 Week Hoogtepunt	HK$14.82
52 Week Laag	HK$6.81
Bèta	-0.47
11 maand verandering	17.57%
3 maanden verandering	18.31%
1 Jaar Verandering	-17.68%
33 jaar verandering	69.95%
5 jaar verandering	28.38%
Verandering sinds IPO	18.75%

Recent nieuws en updates

There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

May 13

Recent updates

There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

May 13

There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump

Apr 24

Charmacy Pharmaceutical Co., Ltd. (HKG:2289) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jan 19

These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well

Oct 25

If EPS Growth Is Important To You, Charmacy Pharmaceutical (HKG:2289) Presents An Opportunity

Sep 17

Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?

May 02

What Type Of Returns Would Charmacy Pharmaceutical's(HKG:2289) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Mar 15

Are Dividend Investors Making A Mistake With Charmacy Pharmaceutical Co., Ltd. (HKG:2289)?

Feb 17

We Wouldn't Rely On Charmacy Pharmaceutical's (HKG:2289) Statutory Earnings As A Guide

Jan 27

Returns On Capital At Charmacy Pharmaceutical (HKG:2289) Paint An Interesting Picture

Jan 09

What Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) ROE Can Tell Us

Dec 22

Reflecting on Charmacy Pharmaceutical's (HKG:2289) Share Price Returns Over The Last Three Years

Nov 29

Rendement voor aandeelhouders

	2289	HK Healthcare	HK Markt
7D	2.2%	-3.4%	0.05%
1Y	-17.7%	-24.4%	11.5%

Rendement versus industrie: 2289 overtrof de Hong Kong Healthcare industrie, die het afgelopen jaar een rendement -24.4 % opleverde.

Rendement versus markt: 2289 presteerde slechter dan Hong Kong Market, dat het afgelopen jaar een rendement van 11.5 % opleverde.

Prijsvolatiliteit

Is 2289's price volatile compared to industry and market?
2289 volatility
2289 Average Weekly Movement	7.1%
Healthcare Industry Average Movement	8.2%
Market Average Movement	9.0%
10% most volatile stocks in HK Market	18.9%
10% least volatile stocks in HK Market	4.2%

Stabiele aandelenkoers: 2289 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van 2289 is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1984	834	Chuanglong Yao	www.chmyy.com

Charmacy Pharmaceutical Co., Ltd. houdt zich bezig met farmaceutische distributie in de Volksrepubliek China. Het bedrijf distribueert westerse geneesmiddelen, Chinese patentgeneesmiddelen, gezondheidsproducten en aanverwante farmaceutische productadviesdiensten naar downstream-distributeurs en retailterminals. Het bedrijf beheert ook Charmacy e-Medicine, een B2B e-commerce platform om online bestellingen te plaatsen, vragen te stellen en betalingen te doen, enz.

Charmacy Pharmaceutical Co., Ltd. Samenvatting

Hoe verhouden de winst en inkomsten van Charmacy Pharmaceutical zich tot de beurswaarde?
2289 fundamentele statistieken
Marktkapitalisatie	HK$1.03b
Inkomsten(TTM)	HK$55.63m
Inkomsten(TTM)	HK$4.82b

18.4x

Koers/Winstverhouding

0.2x

P/S-verhouding

Is 2289 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
2289 resultatenrekening (TTM)
Inkomsten	CN¥4.48b
Kosten van inkomsten	CN¥4.17b
Brutowinst	CN¥314.63m
Overige uitgaven	CN¥262.89m
Inkomsten	CN¥51.74m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	0.48
Brutomarge	7.02%
Nettowinstmarge	1.15%
Schuld/Eigen Vermogen Verhouding	160.2%

Hoe presteerde 2289 op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

3.4%

Huidig dividendrendement

63%

Uitbetalingsratio

2289 Overzicht aandelen

Risicoanalyse

Charmacy Pharmaceutical Co., Ltd. Concurrenten

SEHK:1345

HK$2.4b

SEHK:1931

HK$2.7b

SEHK:6833

HK$365.9m

SEHK:2427

HK$408.5m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Investor sentiment improves as stock rises 17%

First half 2024 earnings released: EPS: CN¥0.25 (vs CN¥0.24 in 1H 2023)

Charmacy Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Investor sentiment deteriorates as stock falls 34%

Upcoming dividend of CN¥0.30 per share

There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

Recent updates

Investor sentiment improves as stock rises 17%

First half 2024 earnings released: EPS: CN¥0.25 (vs CN¥0.24 in 1H 2023)

Charmacy Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Investor sentiment deteriorates as stock falls 34%

Upcoming dividend of CN¥0.30 per share

There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump

New major risk - Share price stability

Investor sentiment improves as stock rises 41%

New major risk - Financial position

Charmacy Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 10 July 2024

Charmacy Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024

Charmacy Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024

Charmacy Pharmaceutical Co., Ltd. (HKG:2289) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Investor sentiment deteriorates as stock falls 17%

Investor sentiment deteriorates as stock falls 18%

These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well

Investor sentiment improves as stock rises 31%

Investor sentiment improves as stock rises 19%

New major risk - Earnings quality

If EPS Growth Is Important To You, Charmacy Pharmaceutical (HKG:2289) Presents An Opportunity

First half 2023 earnings released: EPS: CN¥0.24 (vs CN¥0.19 in 1H 2022)

Investor sentiment improves as stock rises 23%

Charmacy Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 26, 2023

Upcoming dividend of HK$0.50 per share at 6.0% yield

Charmacy Pharmaceutical Co., Ltd. Approves Final Dividend for the Year Ended 31 December 2022, Payable on 31 July 2023

Charmacy Pharmaceutical Co., Ltd. Announces Board Changes

Upcoming dividend of CN¥0.45 per share at 6.2% yield

Charmacy Pharmaceutical Co., Ltd. Announces Ordinary Final Dividend for the Year Ended 31 December 2022, Payable on July 31, 2023

Charmacy Pharmaceutical Co., Ltd. Provides Financial Guidance for the 11 Months Ended 30 November 2022

Less than half of directors are independent

Less than half of directors are independent

First half 2022 earnings released: EPS: CN¥0 (vs CN¥0.24 in 1H 2021)

Charmacy Pharmaceutical Co., Ltd. to Report First Half, 2022 Results on Aug 31, 2022

Charmacy Pharmaceutical Co., Ltd. Announces Executive Changes

Investor sentiment improved over the past week

Insufficient new directors

Charmacy Pharmaceutical Co., Ltd. Announces Change in Board of Directors and Composition of Board Committees

Full year 2021 earnings released

Charmacy Pharmaceutical Co., Ltd. to Report Fiscal Year 2021 Results on Mar 31, 2022

Investor sentiment deteriorated over the past week

Charmacy Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Ended 31 December 2021

Investor sentiment improved over the past week

First half 2021 earnings released: EPS CN¥0.24 (vs CN¥0.29 in 1H 2020)

First half 2021 earnings released: EPS CN¥0.24 (vs CN¥0.29 in 1H 2020)

Charmacy Pharmaceutical Co., Ltd. to Distribute the Final Dividend for the Year Ended 31 December 2020

Upcoming dividend of CN¥0.20 per share

Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?

Full year 2020 earnings released: EPS CN¥0.38 (vs CN¥0.37 in FY 2019)

Full year 2020 earnings released

What Type Of Returns Would Charmacy Pharmaceutical's(HKG:2289) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Charmacy Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day low: HK$4.40

Are Dividend Investors Making A Mistake With Charmacy Pharmaceutical Co., Ltd. (HKG:2289)?

New 90-day low: HK$4.43

We Wouldn't Rely On Charmacy Pharmaceutical's (HKG:2289) Statutory Earnings As A Guide

Returns On Capital At Charmacy Pharmaceutical (HKG:2289) Paint An Interesting Picture

Investor sentiment improved over the past week

What Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) ROE Can Tell Us

Reflecting on Charmacy Pharmaceutical's (HKG:2289) Share Price Returns Over The Last Three Years